Histone deacetylase inhibitors are a class of compounds that interfere with the function of histone deacetylase. They are the enzymes which remove acetyl groups from an N-acetyl lysine amino acid present on a histone, thus wrapping the DNA tightly by the histones.
Globally, an increase in the number of cancer patients across the globe and the need to improve effectiveness of new therapies are the prime growth drivers of histone deacetylase inhibitors market. Additionally, increased R&D activities being carried out for the treatment of cancers & other diseases and increase in collaborations and investments in the HDAC manufacturing are proving to be the major opportunities for the growth of this market. However, reimbursement and uncertainty issues in regards to HDAC inhibitors are the key restraints for the histone deacetylase inhibitors market.
This report identifies the global Histone Deacetylase Inhibitors Market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to Histone Deacetylase Inhibitors Market.
Geographically, Asia-Pacific dominates the Histone Deacetylase Inhibitors Market, and is projected to have the fastest growth. North America, Europe and Rest of the World (RoW) follow Asia-Pacific in terms of market volume. Oncology is expected to be the fastest growing application segment in the global histone deacetylase inhibitors market.